High-dose insulin therapy reduces postoperative liver dysfunction and complications in liver resection patients through reduced apoptosis and altered inflammation

J Clin Endocrinol Metab. 2012 Jan;97(1):217-26. doi: 10.1210/jc.2011-1598. Epub 2011 Oct 26.

Abstract

Context: An exaggerated inflammatory response in patients undergoing major liver resection coupled with poor nutrition diminishes liver regenerative capacity and increases the risk of postoperative complications.

Objectives: Our objective was to evaluate the biological context leading to better clinical outcomes in patients undergoing liver resection coupled with hyperinsulinemic-normoglycemic clamp vs. standard care (insulin sliding care).

Design and setting: This study was a fundamental research analysis of a patient subset from a randomized-controlled study at the McGill University Health Center.

Patients and intervention: Thirty consenting patients participating in a randomized clinical trial for liver resection received either hyperinsulinemic-normoglycemic clamp technique with 24-h preoperative carbohydrate load (intervention) or standard glucose control through insulin sliding scale treatment (control).

Main outcome measures: Liver biopsies and plasma samples were taken at various time points before and after surgery. Primary measures included mRNA quantitation for genes related to insulin signaling, inflammation, and proliferation; proinflammatory cytokines at various time points; and liver function markers. These measurements were associated with clinical outcomes.

Results: The hyperinsulinemic-normoglycemic clamp technique reduced postoperative liver dysfunction, infections, and complications. Markers of energy stores indicated higher substrate availability. Cytokine expression pattern was altered (TNF-α, IL-8, monocyte chemoattractant protein-1, IL-6, IL-10, and C-reactive protein). Apoptosis was markedly reduced, whereas the complement system was unaltered.

Conclusion: The hyperinsulinemic-normoglycemic clamp technique reduced postoperative negative outcomes by suppressing apoptosis. This phenomenon appears to be linked with higher substrate availability and altered cytokine secretion profile and may provide a long-term benefit of this therapy on liver resection patients.

Trial registration: ClinicalTrials.gov NCT00774098.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Apoptosis / drug effects*
  • Dose-Response Relationship, Drug
  • Down-Regulation / drug effects
  • Female
  • Glucose Clamp Technique
  • Hepatectomy / adverse effects
  • Hepatitis / etiology
  • Hepatitis / pathology
  • Hepatitis / prevention & control
  • Humans
  • Inflammation / pathology
  • Inflammation / prevention & control*
  • Insulin / administration & dosage*
  • Insulin / pharmacology
  • Liver / drug effects
  • Liver / immunology
  • Liver / pathology
  • Liver / surgery*
  • Liver Diseases / etiology
  • Liver Diseases / prevention & control*
  • Male
  • Middle Aged
  • Postoperative Complications / prevention & control*
  • Standard of Care

Substances

  • Insulin

Associated data

  • ClinicalTrials.gov/NCT00774098